A number of other equities analysts also recently commented on SRPT. Royal Bank of Canada upped their price objective on shares of Sarepta Therapeutics from $188.00 to $220.00 and gave the stock an outperform rating in a research report on Monday, July 1st. William Blair restated a buy rating on shares of Sarepta Therapeutics in a research report on Friday, August 9th. ValuEngine cut shares of Sarepta Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 8th. Morgan Stanley upped their price target on shares of Sarepta Therapeutics from $165.00 to $220.00 and gave the stock an overweight rating in a research note on Tuesday, July 9th. Finally, Evercore ISI reaffirmed a buy rating and set a $200.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $208.29.
Shares of Sarepta Therapeutics stock opened at $124.95 on Wednesday. The company has a market cap of $9.19 billion, a P/E ratio of -22.88 and a beta of 2.01. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.15 and a current ratio of 8.81. Sarepta Therapeutics has a one year low of $95.21 and a one year high of $165.87. The firm has a fifty day moving average of $145.54 and a two-hundred day moving average of $131.11.
In other Sarepta Therapeutics news, CEO Douglas S. Ingram acquired 16,252 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $123.07 per share, with a total value of $2,000,133.64. Following the purchase, the chief executive officer now owns 424,405 shares in the company, valued at $52,231,523.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Barry acquired 3,700 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was acquired at an average cost of $122.50 per share, for a total transaction of $453,250.00. Following the completion of the purchase, the director now owns 3,177,065 shares in the company, valued at approximately $389,190,462.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 21,252 shares of company stock worth $2,612,634. Corporate insiders own 6.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of SRPT. Evolution Wealth Advisors LLC acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $25,000. Trust Co. of Vermont grew its stake in Sarepta Therapeutics by 2,125.0% in the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 170 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $32,000. Lindbrook Capital LLC acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $35,000. Finally, Quadrant Capital Group LLC acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $51,000. 95.57% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.